The FKBP4 antibody, conjugated with biotin, is a highly specific immunological tool designed to detect and study the FKBP4 protein (Peptidyl-prolyl cis-trans isomerase FKBP4). FKBP4 is a co-chaperone protein associated with HSP90, playing critical roles in steroid hormone receptor signaling, cancer progression, and immune responses . The biotin conjugation enhances the antibody’s utility in assays requiring high-affinity binding, such as ELISA, immunoprecipitation, and fluorescence-based imaging .
The FKBP4 antibody (biotin-conjugated) has been employed in diverse studies:
Cancer Biology: Used to investigate FKBP4’s role in breast cancer progression (via mTORC2/PI3K/Akt signaling) and lung adenocarcinoma (via NF-κB activation) .
Protein Interactomics: Identified FKBP4’s interactions with HSP90, IKK, and PI3K complexes .
Immunodetection: Validated in IHC for FKBP4 expression in tumor tissues and cell lines .
Breast Cancer: FKBP4 depletion inhibits triple-negative breast cancer (TNBC) growth by disrupting PDK1/Akt signaling .
Lung Adenocarcinoma: FKBP4 promotes NF-κB nuclear translocation and tumor metastasis .
Therapeutic Targeting: Biotin-conjugated FKBP4 antibodies enable precise detection of FKBP4 in diagnostic assays, aiding biomarker discovery .